“In the above examples, a sample of the tumor (e.g., biopsy) is tested to determine the molecular signature. Testing may be by genetic sequence tests (e.g., for BCR-ABL, mutated EGFR, or HER2 gene amplification) or tissue protein stains (e.g., for the presence of ER/PR receptors or HER2 protein overexpression). The results of the testing will guide the choice of treatment—it will be personalized for the individual.”